Clinical Trial Results:
A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis
Summary
|
|
EudraCT number |
2019-000660-25 |
Trial protocol |
PL |
Global end of trial date |
23 Apr 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Nov 2021
|
First version publication date |
17 Nov 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CT-P17_3.2
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04171414 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
CELLTRION, Inc.
|
||
Sponsor organisation address |
23, Academy-ro, Yeonsu-gu/Incheon Metropolitan City, Korea, Republic of,
|
||
Public contact |
MinJi Ma, Celltrion, '+82 328505780, minji.ma@celltrion.com
|
||
Scientific contact |
SungHyun Kim, Celltrion, '+82 328504100, sunghyun.kim@celltrion.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 Apr 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
23 Apr 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate usability of CT-P17 auto-injector (AI) assessed by patients at Week 4.
|
||
Protection of trial subjects |
Hypersensitivity/allergic reactions will be assessed prior to the study drug administration and 1 hour (±10 minutes) after the end of the study drug administration by additional vital sign measurements including BP, heart and respiratory rates, and body temperature.
In addition, hypersensitivity will be monitored by routine continuous clinical monitoring including patient-reported signs and symptoms. In case of hypersensitivity, emergency medication and equipment, such as adrenaline, antihistamines, corticosteroids, and respiratory support including
inhalational therapy, oxygen, and artificial ventilation must be available and any types of ECG can be
performed.
For patients who experience or develop life threatening treatment-related anaphylactic reactions, study
drug must be stopped immediately and the patient withdrawn from the study.
|
||
Background therapy |
Methotrexate was co-administered by oral or parenteral at a dose of between 12.5 to 25 mg/week, or 10 mg/week if intolerant to a higher dose, throughout the study. Folic acid was co-administered at a dosage of at least 5 mg/week by oral dose throughout the duration of study. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
13 Aug 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 62
|
||
Worldwide total number of subjects |
62
|
||
EEA total number of subjects |
62
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
56
|
||
From 65 to 84 years |
6
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
First patient first visit: 13 August 2019. This study was conducted at 5 study centers in Poland. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Male or female patients with moderate to severe active RA diagnosed according to the 2010 ACR/EULAR classification criteria, despite ongoing treatment with MTX over at least 12 weeks. | ||||||||||||
Pre-assignment period milestones
|
|||||||||||||
Number of subjects started |
73 [1] | ||||||||||||
Number of subjects completed |
62 | ||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||
Reason: Number of subjects |
Inclusion/exclusion criteria not met: 8 | ||||||||||||
Reason: Number of subjects |
Consent withdrawn by subject: 3 | ||||||||||||
Notes [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: The subject number is correct who has started screening activities. |
|||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Treatment Period (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Arms
|
|||||||||||||
Arm title
|
CT-P17 | ||||||||||||
Arm description |
CT-P17 (Adalimumab) EOW from Week 0 to Week 24. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
CT-P17
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled pen
|
||||||||||||
Routes of administration |
Solution for injection
|
||||||||||||
Dosage and administration details |
40mg EOW, co-administered with MTX; 12.5–25 mg/week or 10 mg/week if intolerant to a higher dose and folic acid (≥5 mg/week).
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CT-P17
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
CT-P17 (Adalimumab) EOW from Week 0 to Week 24. | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
CT-P17
|
||
Reporting group description |
CT-P17 (Adalimumab) EOW from Week 0 to Week 24. |
|
|||||||||||||||||||||||||||
End point title |
The usability as assessed by patients rating using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4 [1] | ||||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||
End point timeframe |
Week 4
|
||||||||||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Summarized using descriptive statistics |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||
End point title |
Patient’s rating of PRE- and POST-SIAQ at Weeks 0, 2, and 24 | ||||||||||||||||||||||||||
End point description |
Here result from week 24 was uploaded
|
||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||
End point timeframe |
Weeks 0,2,24
|
||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Observer’s rating of successful self-injection using self-injection assessment checklist at Weeks 0, 2, 4, and 24 | ||||||||||||||||||||||
End point description |
|||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Week 0,2,4,24
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Mean for actual values and change from baseline in DAS28 (CRP and ESR) | ||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Week 8,16,24
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the date the patient signed the ICF until EOS/ED visit
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
CT-P17
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 3% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Nov 2019 |
Summary of significant changes included the following:
- Changed number of planned study population
- Included anaphylactic reactions as AESI.
- Differentiated the definition from the Safety Population.
- Deleted time limitation regarding report of all AEs related to hypersensitivity and allergic reactions
- Updated details regarding IGRA and active TB
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
During the latter half of the study period, the COVID-19 pandemic broke out. For the majority of patients, only EOS visit was affected, the adjusted procedure including remote follow-up was conducted. |